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a b s t r a c t 
Background: Malaria during pregnancy is a major contributor to the global burden of adverse birth out- 
comes including fetal growth restriction, preterm birth, and fetal loss. Recent evidence supports a role 
for angiogenic dysregulation and perturbations to placental vascular development in the pathobiology 
of malaria in pregnancy. The Angiopoietin-Tie2 axis is critical for placental vascularization and remodel- 
ing. We hypothesized that disruption of this pathway would contribute to malaria-induced adverse birth 
outcomes. 
Methods: Using samples from a previously conducted prospective cohort study of pregnant women in 
Malawi, we measured circulating levels of angiopoietin-1 (Angpt-1) and Angpt-2 by Luminex (n = 1392). 
We used a preclinical model of malaria in pregnancy ( Plasmodium berghei ANKA [PbA] in pregnant BALB/c 
mice), genetic disruption of Angpt-1 ( Angpt1 + / − mice), and micro-CT analysis of placental vasculature to 
test the hypothesis that disruptions to the Angpt-Tie2 axis by malaria during pregnancy would result in 
aberrant placental vasculature and adverse birth outcomes. 
Findings: Decreased circulating levels of Angpt-1 and an increased ratio of Angpt-2/Angpt-1 across preg- 
nancy were associated with malaria in pregnancy. In the preclinical model, PbA infection recapitulated 
disruptions to the Angiopoietin-Tie2 axis resulting in reduced fetal growth and viability. Malaria de- 
creased placental Angpt-1 and Tie2 expression and acted synergistically with reduced Angpt-1 in het- 
erozygous dams ( Angpt1 + / −), to worsen birth outcomes by impeding vascular remodeling required for 
placental function. 
Interpretation: Collectively, these data support a mechanistic role for the Angpt-Tie2 axis in malaria in 
pregnancy, including a potential protective role for Angpt-1 in mitigating infection-associated adverse 
birth outcomes. 
Funding: This work was supported by the Canadian Institutes of Health Research (CIHR), Canada Re- 
search Chair, and Toronto General Research Institute Postdoctoral Fellowship Award. The parent trial was 
supported by the European & Developing Countries Clinical Trials Partnership and the Malaria in Preg- 
nancy Consortium, which was funded by the Bill & Melinda Gates Foundation. The funders had no role 
in design, analysis, or reporting of these studies. 
© 2021 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
https://doi.org/10.1016/j.ebiom.2021.103683 
2352-3964/© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 




































































Research in context 
Evidence before this study 
Despite progress in preventing and treating Plasmod- 
ium falciparum malaria in pregnancy, the global burden 
of malaria-related adverse birth outcomes (e.g., low birth 
weight, preterm birth, and foetal loss) remains high. Ex- 
isting evidence implicates disruptions to placental vascu- 
lar development as a key mediator of the pathobiology of 
malaria-associated adverse birth outcomes. The angiopoietin 
signalling axis has been implicated in the pathogenesis of se- 
vere malaria in non-pregnant individuals. Furthermore, there 
is evidence in cross-sectional studies for systemic and placen- 
tal dysregulation of Angpt-1 and Angpt-2 by P. falciparum in- 
fection during pregnancy. However, a mechanistic role for the 
angiopoietin signalling family in the pathogenesis of malaria 
in pregnancy has not been established. 
Added value of this study 
Here, we explore a putative mechanistic role for the 
Angpt-Tie2 signalling axis in the pathogenesis of malaria in 
pregnancy. We used longitudinal clinical data from a large 
cohort of pregnant women to extend existing cross-sectional 
data and characterize the longitudinal dynamics of Angpt-1 
and Angpt-2 across pregnancies complicated by malaria. We 
used a preclinical model of malaria in pregnancy, combined 
with genetic reduction of Angpt-1 ( Angpt1 + / −), and micro- 
CT imaging of placental vasculature to show that Angpt-1 
may play a putative protective role in the pathogenesis of 
malaria in pregnancy via compensatory placental vascular re- 
modelling. 
Implications of all the available evidence 
Our data provide preliminary evidence for a mecha- 
nistic link between malaria-associated disruptions to the 
Angpt-Tie2 axis, aberrant placental vascular development and 
remodelling, and adverse birth outcomes. Previous cross- 
sectional studies in Plasmodium -infected pregnancies showed 
disruptions to the angiopoietins at delivery, at which point 
intervention is futile. Here, we combined clinical and preclin- 
ical data to provide a more comprehensive picture of the dis- 
ruption of Angpt-1 and Angpt-2 homeostasis across gestation 
and its subsequent impact on placental vascular development 
and birth outcomes. 
. Introduction 
Despite progress in preventing and treating Plasmodium falci- 
arum malaria in pregnancy, the global burden of malaria-related 
dverse birth outcomes (e.g., low birth weight, preterm birth, and 
oetal loss) remains high [ 1 , 2 ]. Advances in our understanding of
alaria-associated adverse birth outcomes have implicated early 
ysregulation of inflammatory and angiogenic pathways, and con- 
equent disruptions to placental vascular development, as key me- 
iators of its pathobiology [2–6] . 
Developing a healthy placental vascular system is essential to 
ustain foetal growth and support a successful pregnancy. Placen- 
al vascular development is a complex process that requires tight 
egulation and crosstalk between inflammatory and angiogenic sig- # Corresponding author: Dr. Kevin C. Kain, University Health Network, Toronto 
eneral Hospital, MaRS Centre, TMDT, 10th Floor 10-351, Toronto, Ontario M5G 1L7, 
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2 alling pathways [ 7 , 8 ]. There is considerable evidence supporting 
he hypothesis of a hierarchical relationship between maternal in- 
ection and immune activation, dysregulation of angiogenic path- 
ays and placental development, and adverse birth outcomes [re- 
iewed in [9] ]. The angiopoietin protein family has critical roles 
n placental and embryonic development including regulation of 
ngiogenesis, trophoblast function, and spiral artery remodelling 
 10 , 11 ]. Angiopoietin-1 (Angpt-1) and its antagonist angiopoietin- 
 (Angpt-2), both signal through the Tie2 receptor and their re- 
pective placental expressions are spatially and temporally coordi- 
ated across pregnancy [ 10 , 12-14 ]. Angpt-1 stabilizes vasculature 
nd promotes vessel maturation, while Angpt-2 destabilizes vascu- 
ature to promote plasticity and vascular remodelling [15] . Regula- 
ion of the angiopoietins requires a fine balance, and disruptions of 
ngpt-1, Angpt-2, and the Angpt-2/Angpt-1 ratio have been linked 
o pathological pregnancies and adverse birth outcomes [ 3 , 5 , 10 , 16-
8 ]. 
Clinical and preclinical studies of paediatric and adult P. falci- 
arum infection support a mechanistic role for Angpt-1 and Angpt- 
 in the pathogenesis of severe malaria in non-pregnant individu- 
ls [19–23] . Moreover, there is evidence in cross-sectional studies 
or systemic and placental dysregulation of Angpt-1 and Angpt-2 
y P. falciparum infection during pregnancy [ 3 , 5 , 24 , 25 ]. We previ-
usly reported that disruptions to C5a-C5a receptor signalling in 
reclinical and clinical malaria in pregnancy led to foetal growth 
estriction via aberrant placental vascular development [3] . In that 
rospective study of pregnant women in Malawi, structural equa- 
ion modelling was applied to statistically demonstrate that de- 
reases in circulating Angpt-1 were downstream of C5a in its me- 
iation of adverse birth outcomes [3] . However, a mechanistic 
ole for the angiopoietin signalling family in the pathogenesis of 
alaria in pregnancy has not been established. 
Here we show that the Angpt-Tie2 axis plays a role in the 
athogenesis of malaria in pregnancy. In a longitudinal cohort 
tudy, we extend existing cross-sectional data by showing that 
ngpt-1 is decreased and the Angpt-2/Angpt-1 ratio is increased 
cross pregnancies complicated by Plasmodium falciparum infec- 
ion. Using an experimental model of malaria in pregnancy, we 
how that Angpt-1 plays a potential protective role in the patho- 
enesis of antenatal malaria via compensatory placental vascular 
emodelling. Collectively, our data suggest a mechanistic role for 
ngpt-1 in the pathogenesis of malaria and malaria-associated pla- 
ental vascular development and adverse birth outcomes. 
. Methods 
.1. Clinical cohort study design and analyte data 
This study cohort was nested within a three-site, two-arm, ran- 
omized superiority trial of malaria prevention during pregnancy 
n Malawi [26] . Between 2011 and 2013, HIV-negative pregnant 
omen were enrolled in the parent trial and randomized to re- 
eive either intermittent preventative treatment in pregnancy with 
ulfadoxine-pyrimethamine (IPTp-SP), or intermittent screening 
nd treatment in pregnancy with dihydroartemisinin-piperaquine 
ISTp-DP). Women enrolled in the parent trial attended 3-4 ante- 
atal visits in the second and third trimester, scheduled every 4-6 
eeks. Women were tested for peripheral malaria at each sched- 
led (3-4) and unscheduled (up to 8 [26] ) visit including deliv- 
ry, by real-time polymerase chain reaction (PCR). At delivery, the 
resence of placental malaria (assessed by placental histopathol- 
gy and/or by PCR in placental blood), as well as birth weight and 
estational age were recorded. Gestational age was determined by 
ltrasound as described [26] . Comprehensive information on par- 
nt trial inclusion/exclusion criteria, malaria testing, and treatment 
ourses has been published [26] . 




























































































































A maternal plasma sample was collected at each scheduled an- 
enatal visit. Of the 1873 participants enrolled in the parent trial, 
omen were included in this nested study of placental pathobi- 
logy if they met the inclusion criteria for plasma analyte test- 
ng as described [2] , including enrolment in the parent trial < 24 
eeks gestation and an available plasma sample (kept frozen at 
80 °C) [n = 1628]. In addition, participants without a known birth 
utcome or placental malaria status were excluded from the cur- 
ent analysis to reach the final cohort size of n = 1392. Women en-
olled in the parent trial that were excluded from our final co- 
ort had similar demographic characteristics to our cohort includ- 
ng treatment group allocation, socioeconomic status, rates of pla- 
ental malaria, rates of adverse live birth outcomes, and primigra- 
idity (all p > 0.05; Wilcoxon rank sum (continuous) or chi-square 
est (categorical)). Women excluded from our cohort had a higher 
edian age (22 vs. 21; Wilcoxon rank sum, p = 0.006), and higher 
ates of foetal loss (5.1% vs. 1.3%; chi-square test, p < 0.0 0 01). 
In this study, the primary malaria outcome was placental 
alaria. Placental malaria was defined by placental histology (in- 
luding past and active infections) and/or infection in the placental 
lood by PCR. Placental malaria was chosen based on the study’s 
ocus on placental vascular development. Adverse birth outcomes 
ere defined as: adverse live birth outcomes, which included low 
irth weight ( < 2500g), small-for-gestational age [27] , and preterm 
irth ( < 37 weeks gestation); or foetal loss, which included miscar- 
iage and stillbirth [26] . Multianalyte Luminex Human Discovery 
ssay (R&D Systems, Minneapolis, MN; custom plate LXSAHM-01) 
as used to measure angiopoietin-1 (Angpt-1; 1:2 dilution) and 
ngiopoietin-2 (Angpt-2; 1:2 dilution) in maternal plasma at up to 
hree gestational windows per woman that corresponded with an- 
enatal visits (13-23 weeks gestation, 28-33 weeks gestation, and 
4-36 weeks gestation) [2] . All samples were processed according 
o manufacturers’ instructions. The methods of assessment were 
he same across groups, and malaria status and birth outcomes 
ere unknown to the individuals performing the analyte assays. 
.2. Statistical analyses of clinical data 
Statistical analyses of clinical data were performed using R ver- 
ion 4.0.3 (R Core Team, 2020). Relative risk (with 95% confidence 
ntervals) of live adverse birth outcomes or foetal loss accord- 
ng to maternal placental malaria status was calculated using log- 
inomial regression. Models were adjusted for factors (chosen a 
riori ) known to be associated with adverse birth outcomes, in- 
luding gestational age at enrolment, maternal age, socioeconomic 
tatus (calculated as described in [26] ), and parent trial treatment 
roup. In this cohort, gravidity was strongly correlated with ma- 
ernal age (Spearman’s rho = 0.84; p < 0.0 0 01), and so it was not
ncluded as a covariate in log-binomial regression or linear mixed- 
ffects models to avoid problems with multicollinearity. However, 
s primigravids are more susceptible to placental malaria and ex- 
erience more severe birth outcomes in the context of P. falci- 
arum infection [1] , analyses were stratified by gravidity (primi- 
ravidae and multigravidas) to investigate its impact as an effect 
odifier. Angiopoietin analyte data were log-transformed for lon- 
itudinal analysis. To assess the impact of placental malaria on lon- 
itudinal angiopoietin concentrations, as well as differences in lon- 
itudinal angiopoietin concentrations in pregnancies resulting in 
dverse birth outcomes, we used linear mixed-effects modelling 
LME) with the lme4 package in R [28] . We modelled repeated 
easures angiopoietin data as a continuous dependent variable. 
or each analyte we built a null model, which included maternal 
ge, socioeconomic status, and a restricted cubic spline [29] of ges- 
ational age as fixed effects, and a by-participant intercept as a 
andom effect. Parent trial treatment group (IPTp-SP vs. ISTp-DP) 
as not associated with demographic variables, malaria status, or 3 nalyte data (Supplementary Table 1); however, treatment group 
as included as a fixed effect in all models to account for the 
arent trial design. The effect of placental malaria on angiopoietin 
oncentrations across pregnancy was analysed by adding placental 
alaria status as a fixed effect in a second model. A third model 
ncluded an interaction term between the spline of gestational age 
nd placental malaria status to account for variation in the effect 
f placental malaria status on angiopoietin concentration accord- 
ng to gestational age. Models were compared for best fit using a 
ikelihood ratio test. Longitudinal analysis of angiopoietins across 
regnancy according to birth outcome was conducted in the same 
ay; however, placental malaria was included as a fixed effect in 
ll models and birth outcome was added to the null model as the 
ariable of interest. 
.3. Experimental model of malaria in pregnancy 
To examine the role of Angpt-1 in the pathology of malaria 
n pregnancy, we used a well-validated experimental model of 
alaria in pregnancy [ 3 , 4 , 30 ]. For experiments measuring Angpt- 
 and Angpt-2 dynamics across pregnancy, wildtype BALB/c female 
nd male mice (7-8 weeks old; purchased from Jackson Labora- 
ories [stock no: 0 0 0651] were paired (triad breeding) for timed- 
ating. Mice purchased from a commercial supplier were allowed 
o acclimatize for one week before commencement of experiments. 
or genetic experiments, Angpt1 + / − mice were bred starting from 
ngpt1 del on a 129Sv/J mixed background obtained from our col- 
aborator Dr. Sue Quaggin (Samuel Lunenfeld Research Institute, 
oronto, ON). Targeted mutations were transferred to the BALB/c 
ackground by backcrossing to wild type BALB/c mice for 10 gen- 
rations. Angpt1 + / − and wildtype female littermate controls were 
aired (triad breeding) with wildtype BALB/c males purchased 
rom Jackson Laboratories (8-15 weeks old; [stock no: 0 0 0651] for 
imed-mating. When mating was confirmed (by presence of vagi- 
al plug), female mice were weighed and separated into cages 
f 3-4 potentially pregnant females. Individual mice were iden- 
ified using a standard ear-punch system. On gestational (G) day 
3, naturally mated pregnant dams were infected with Plasmod- 
um berghei ANKA (MR4 [ATCC/MR4] Malaria Research & Reference 
eagent Resource Center, cat#MRA-311) thawed from cryopreser- 
ation and passaged through a male BALB/c mouse. Dams were in- 
ected intravenously via the lateral tail vein with either 10 6 par- 
sitized erythrocytes (infected group) prepared in Gibco Roswell 
ark Memorial Institute (RPMI) medium (ThermoFisher), or the 
ame volume of RPMI alone (uninfected control group). After in- 
ection, mice were monitored daily and euthanized if they showed 
vert signs of distress (hypothermia, loss of > 20% body weight, 
uffled coat, inactivity). Experiments were planned to achieve a 
ample size of 5 biological replicates (pregnant dams) per group, 
ith a minimum of 2 experimental replicates. Final sample size 
as determined by success of timed pregnancy (assessed twice be- 
ore randomization: by weight gain ≥1.5g on G9 and weight gain 
2.5g on G13). Mice that reached the pre-established weight gain 
ut-offs were included in the study and randomized to exposure 
roup (i.e., infected vs. uninfected) on G13, by alternating assigna- 
ion. To reduce confounding, dams within a single cage were split 
etween infected and uninfected exposure groups and all cages 
ere located together within the animal housing facility. On the 
ay of sacrifice, mice were excluded from the cohort if it was dis- 
overed by dissection that they were not pregnant. 
Pregnant dams were sacrificed with carbon dioxide inhalation 
2.4L/min/20% filling; using an 1l.9L container). As the infected 
ams are visibly ill, laboratory personnel were not blinded at this 
tage. To reduce bias, all sacrifices for an experiment were per- 
ormed sequentially, within the same timeframe. Maternal whole 
lood ( ∼50 0-10 0 0 μL) was collected by cardiac puncture with 




















































































































eparin, spun down to isolate plasma, and plasma was stored at 
80 °C for future analysis. Foetuses were dissected from uteri and 
olk sacs and weighed. Foetal viability was assessed by visual ex- 
mination and pedal withdrawal reflex. Placentas were snap-frozen 
n liquid nitrogen and stored at -80 °C. For assessment of mater- 
al data (i.e., peripheral plasma angiopoietin levels), each dam was 
onsidered an experimental unit. For assessment of foetal and pla- 
ental data (i.e., foetal weight and viability, placental qRT-PCR, pla- 
ental vasculature), each foetus and/or placenta was an experimen- 
al unit. 
.4. Placental transcript analysis 
Levels of Angpt-1, Angpt-2, and Tie2 were determined by quan- 
itative real-time PCR (qRT-PCR) as described previously [5] . Briefly, 
NA was extracted from snap-frozen mouse placentas after ho- 
ogenization in TRIzol (Invitrogen, cat#15596018) as per man- 
facturer’s instructions. RNA was treated with Dexoyribonucle- 
se I (RNase-free) (Thermo Scientific, cat#EN0521) and reverse 
ranscribed to complimentary DNA (cDNA) with iScript cDNA 
ynthesis Kit (Bio-Rad, cat#1708891) with oligo (dT) 18 primers. 
DNA was amplified and quantified in triplicate by qRT-PCR 
ith LightCycler® 480 SYBR Green I Master (Roche Diagnostics, 
at#04707516001) and 1 μM of both forward and reverse primers 
sing a Roche Light Cycler® 480 (Roche, Serial #20377). Samples 
ere run in triplicate. Transcript expression levels were calculated 
ompared to a standard curve of mouse genomic DNA included 
n each plate and normalized to average GAPDH expression levels. 
ee supplementary methods for primer sequences and thermocy- 
ling conditions. Laboratory personnel were blinded to experimen- 
al groups and outcomes. 
.5. Mouse maternal plasma analyte measurements 
Circulating mouse maternal plasma levels of Angpt-1 (1:20 di- 
ution, R&D Systems, cat #DY923) and Angpt-2 (1:160 dilution, 
&D Systems, cat#MANG20) were measured by enzyme-linked im- 
unosorbent assay (ELISA) from samples stored at -80 °C. Samples 
ere processed according to manufacturer’s protocols. Laboratory 
ersonnel were blinded to experimental groups and outcomes. 
.6. Fetoplacental perfusions and micro-computed tomography 
Placentas were perfused via umbilical artery cannulation as de- 
cribed previously [ 3 , 31 ]. Briefly, uteri were collected from preg- 
ant mice on G18, dipped in iodine and placed in cold Dulbecco’s 
odified Eagle’s Medium (DMEM) to anesthetize the foetuses. 
nce removed from the uterus with fetoplacental vascular connec- 
ion intact, foetuses were individually warmed with saline to reini- 
iate heartbeat and placental blood flow. Placentas were perfused 
ith 2% xylocaine and 100 IU/mL heparin in saline followed by 
adio-opaque silicone rubber contrast agent (Microfil ®; Flow Tech- 
ology, Carver, MA) until capillaries were visibly perfused. Umbil- 
cal vessels were clamped to maintain pressure and left to set for 
ne hour. Placentas were fixed in 10% phosphate-buffered forma- 
in for 24 hours and mounted in 1% agar for imaging by micro- 
omputed tomography (micro-CT) using a Bruker Skyscan 1272 
canner (Bruker Skyscan, Antwerp, Belgium). Three-dimensional 
ata sets were acquired with each specimen rotated 360 ° and a 
esolution of 7.1 μm. The placental vasculature was automatically 
egmented using a previously described algorithm that identified 
essel segments and bifurcations [32] . Detection of vessels with 
 diameter smaller than 35 μm was unreliable, and therefore the 
erminal segments of the vascular tree were pruned to 35 μm to 
mprove data consistency. Resistance of the foeto-placental arterial 
ascular network was calculated using a combination of standard 4 ormulas for resistances in parallel and in series as described pre- 
iously [31] . Haemodynamic calculations assumed Poiseuille’s law 
or flow of fluid through a pipe-like structure; equal pressure at 
ach terminal vessel; and a correction factor modelling blood vis- 
osity changes in small vessels derived using adult blood [33] . Lab- 
ratory personnel were blinded to experimental groups and out- 
ome. 
.7. Statistical analyses of experimental studies 
Statistical analyses of experimental studies were performed us- 
ng GraphPad Prism v9 (GraphPad Software, LLC). For experimen- 
al malaria in pregnancy time course data, each time point repre- 
ents separate groups of mice (from one experimental cohort to 
eep conditions consistent) at the different gestational ages be- 
ause specimen collection for analysis required maternal sacrifice. 
herefore, repeated measures analysis was not appropriate and 
ime course data were analysed using two-way ANOVA with Bon- 
erroni’s multiple comparisons test to compare groups at each ges- 
ational age. Assumptions of two-way ANOVAs were checked by 
isual inspection of residuals (for heteroscedasticity) and Shapiro- 
ilk’s test for normality of residuals. When these assumptions 
ere not met, data were log-transformed. If assumptions were still 
ot satisfied, time course data were analysed using multiple Mann- 
hitney tests with Holm-Sidak correction for multiple compar- 
sons. Maternal plasma and placental qRT-PCR data at G19 were 
nalysed using one-way ANOVA with Tukey’s multiple comparisons 
est. ANOVA assumptions were assessed using Brown-Forsythe and 
artlett’s tests for homogeneity of variance and Shapiro-Wilk’s test 
or normality of residuals. When these assumptions were not met, 
ata were log-transformed. If assumptions were still not met, these 
ata were analysed using Kruskall-Wallis non-parametric ANOVA 
ith Dunn’s test for multiple comparisons. As ANOVA results can 
e sensitive to outliers, outliers were identified using the ROUT 
ethod with a conservative threshold (Q = 0.1%) to avoid false 
etection. No outliers (n = 2 across all experiments) were removed 
ecause sensitivity analysis showed they did not influence the re- 
ults. Differences in foetal viability were assessed using Fisher’s ex- 
ct test. The cumulative distributions of vessel diameters for the 
lacentas were fit with a natural spline with eight degrees of free- 
om. A two-way ANOVA was used to determine whether there 
as an effect of treatment group on the spline parameters, with 
 Dunn’s multiple comparison post hoc test. 
.8. Ethics 
The parent clinical trial was registered with the Pan-African 
linical Trials Registry [PACTR2011030 0 0280319] and the ISRCTN 
egistry [ISRCTN69800930]. Ethical approval for clinical work was 
btained from the Liverpool School of Tropical Medicine [Protocol 
10.74)], the Malawian National Health Science Research Commit- 
ee [NHSRC 916], and University Health Network Research Ethics 
oard (Toronto) [14-7313 Biomarkers in Pregnancy]. Written in- 
ormed consent was acquired from all study participants. All exper- 
mental protocols involving animals were prepared and approved 
y the University Health Network Animal Care Committee [UHN 
CC] (Animal Use Protocol (AUP) #3568) before study initiation. 
ll work was done in compliance with animal husbandry standard 
perating procedures set out by UHN ACC. 
Data availability: Detailed AUP procedures, including housing 
nd husbandry, ethical animal care, and humane endpoints can be 
rovided upon request. All human and animal data that support 
he findings of this study are available upon request from the cor- 
esponding author, Kevin C. Kain. 
Role of funding source: The funders had no role in design, anal- 
sis, or reporting of these studies. 
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Table 1 
Population characteristics by placental malaria status of pregnant women enrolled in a prospective cohort in Malawi. 
Entire Cohort Placental Malaria Negative a Placental Malaria Positive a 
Median [IQR] or n (%) p -value b 
Baseline Characteristics n = 1392 n = 892/1392 (64.1) n = 500/1392 (35.9) 
Age (years) 21 [18, 25] 23 [20, 27] 19 [17, 22] < 0 .0001 
Primigravid 484 (34.8) 219 (24.6) 265 (53.0) < 0 .0001 
Gestational age at enrolment (weeks) 20.0 [18.3, 21.7] 20.1 [18.2, 22.0] 20.3 [18.6, 22.3] 0 .154 
Socioeconomic status c -1.02 [-1.49, 0.43] -0.90 [-1.45, 0.90] -1.19 [-1.52, -0.06] < 0 .0001 
Treatment arm (IPTp-SP) 688 (49.4) 454 (50.9) 234 (46.8) 0 .158 
Birth Outcomes d 
Adverse live birth outcomes 404 (29.5) 232 (26.3) 172 (35.3) < 0 .001 
Fetal loss 18 (1.3) 7 (0.8) 11 (2.2) 0 .046 
a Placental malaria was defined by placental histology (includes past and active infection) and/or infection in the placental blood by PCR at 
delivery. b Comparing placental malaria negative and positive. c 3 women were missing data for socioeconomic status (n = 1389). d Adverse 
live birth outcomes include low birth weight, small-for-gestational age, or preterm birth; foetal loss includes miscarriage or stillbirth. 24 
women were missing data for adverse live birth outcomes (n = 1368); however, all women had data for foetal loss (n = 1392). Abbreviations: 
Intermittent preventative treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP); interquartile range (IQR). 
Figure 1. Placental malaria is associated with dysregulation of the maternal angiopoietin axis across pregnancy. (a to c) Longitudinal changes in maternal concentrations of 
(a) angiopoietin-1 (Angpt-1), (b) angiopoietin-2 (Angpt-2), and (c) the Angpt-2/Angpt-1 ratio across pregnancy by placental malaria status (negative or positive) in whole 
cohort (n = 1389 subjects, n = 2975 observations). Three women were not included in the analysis because of missing covariate data (socioeconomic status). Longitudinal 
regression lines depict linear mixed effects model-predicted, back-transformed values and 95% confidence intervals of analytes across pregnancy stratified by placental 
malaria status, while holding other fixed effects constant [57] . P-value overlaid on graphs determined by likelihood ratio test comparing the model with placental malaria 
status to the null model (model without). All models adjusted for (fixed effects) a restricted cubic spline of gestational age, maternal age and socioeconomic status at 














































.1. Placental malaria is associated with adverse birth outcomes and 
ltered Angpt-2/Angpt-1 concentrations across pregnancy 
We examined the relationships between placental malaria, birth 
utcomes, and circulating levels of Angpt-1 and Angpt-2 across 
regnancy in a cohort of pregnant women in Malawi (n = 1392). 
here was evidence for placental malaria in one third of the cohort 
n = 500, 35.9%). In 404 pregnancies (29.0%) there were adverse live 
irth outcomes, and in 18 (1.3%), foetal loss ( Table 1 ). 
After adjusting for demographic variables, placental malaria was 
ssociated with an increased relative risk of adverse live birth 
utcomes (aRR [95% CI]: 1.28 [1.07, 1.52], log-binomial regression 
 = 0.007) and foetal loss (aRR [95% CI]: 3.20 [1.21, 8.98], log- 
inomial regression p = 0.021) (Figure S1). Women with evidence 
f placental malaria also had decreased circulating Angpt-1 across 
regnancy (adjusted LME model: β [95% CI]: -0.13 [-0.21, -0.04], 
 = 0.003) and an increased ratio of Angpt-2/Angpt-1 (adjusted LME 
odel: β [95% CI]: 0.17 [0.07, 0.28], p = 0.001), compared to women 
ith no evidence of placental malaria ( Figure 1 ). Women with ev- 
dence of peripheral malaria by PCR at any point across pregnancy 
ad a similar profile of decreased Angpt-1 (adjusted LME p = 0.049; 
igure S2a) and an increased Angpt-2/Angpt-1 ratio (adjusted LME 
 = 0.024; Figure S2c) across pregnancy. We stratified the analysis 
o assess gravidity (primigravidae and multigravidas) as a potential m
5 ffect modifier of the relationship between placental malaria and 
ngiopoietins. In primigravidae, women with placental malaria had 
ecreased Angpt-1 (adjusted LME, p = 0.043), increased Angpt-2 
adjusted LME, p = 0.040), and an increased ratio of Angpt-2/Angpt- 
 (adjusted LME, p = 0.006) across pregnancy ( Figure 2 , a-c). Multi-
ravidity was associated with decreased Angpt-1 (adjusted LME, 
 = 0.016) in women who had evidence of placental malaria; how- 
ver, there were no differences in Angpt-2 or the Angpt-2/Angpt-1 
atio ( Figure 2 , d-f). 
The dynamics of Angpt-1 (adjusted LME, p = 0.014; Figure S3a), 
ngpt-2 (adjusted LME, p < 0.001; Figure S3b), and the Angpt- 
/Angpt-1 ratio (adjusted LME, p < 0.001; Figure S3c) were also al- 
ered across pregnancies that resulted in adverse live birth out- 
omes, after controlling for placental malaria. These analyses re- 
ealed an interaction between gestational age and adverse birth 
utcomes, indicating that the association between the angiopoi- 
tins and adverse live birth outcomes varied according to gesta- 
ional age (Figure S3a-c). 
.2. Experimental malaria in pregnancy dysregulates circulating 
aternal angiopoietins and mRNA expression of angiopoietins and 
ie2 in the placenta 
We used a well characterized experimental model of malaria in 
regnancy to investigate a potential mechanistic role for angiopoi- 
tin signalling in mediating adverse birth outcomes. This model 
ost closely resembles infections in primigravidae. The preclini- 
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Figure 2. Placental malaria is differentially associated with dysregulation of the maternal angiopoietin axis across pregnancy in primigravid pregnancies and multigravid 
pregnancies. (a to c) Longitudinal changes in maternal concentrations of angiopoietin-1 (Angpt-1), angiopoietin-2 (Angpt-2), and the Angpt-2/Angpt-1 ratio across pregnancy 
in by placental malaria status (negative or positive) in primigravid (n = 481 subjects; n = 1006 observations) and (d to f) multigravid pregnancies (n = 908 subjects; n = 1969 
observations). Three women were not included in the analysis because of missing covariate data (socioeconomic status). Longitudinal regression lines depict linear mixed 
effects model-predicted, back-transformed values and 95% confidence intervals of analytes across pregnancy stratified by placental malaria status, while holding other fixed 
effects constant [57] . P-value overlaid on graphs determined by likelihood ratio test comparing the model with placental malaria status to the null model (model without). 
All models adjusted for (fixed effects) a restricted cubic spline of gestational age, maternal age and socioeconomic status at enrolment, parent trial treatment group, and a 





















































al model of malaria emulated the pathology of human malaria 
n pregnancy, including reduced foetal weight (multiple Mann- 
hitney with Holm Sidak correction, p < 0.0 0 01; Figure 3 a) and vi-
bility (Fisher’s exact test, p < 0.0 0 01; 3b). An assessment of exper- 
mental malaria pathology over the course of pregnancy showed 
 reduction in foetal weight in P. berghei -infected pregnant mice 
tarting at G18 (multiple Mann-Whitney with Holm Sidak correc- 
ion, p < 0.001; Figure 3 a). This coincided with a reduction in ma-
ernal plasma Angpt-1 and an increase in maternal plasma Angpt-2 
nd the Angpt-2/Angpt-1 ratio (two-way ANOVA with Bonferroni’s 
ultiple comparisons, p < 0.01; Figure 3 c, 3 e, and 3 g), which reca-
itulates the longitudinal clinical findings in primigravidae. Both 
oetal growth restriction and increased levels of Angpt-2 were pre- 
eded by a significant reduction in circulating Angpt-1 starting at 
16 in infected dams (two-way ANOVA with Bonferroni’s multiple 
omparisons; p < 0.05; Figure 3 c). 
In placental tissue, Angpt-1 mRNA was significantly reduced 
two-way ANOVA with Bonferroni’s multiple comparisons, p < 0.01; 
igure 3 d) and the Angpt-2/Angpt-1 ratio was increased (two-way 
NOVA with Bonferroni’s multiple comparisons, p < 0.05; Figure 3 h) 
n P. berghei -infected dams compared to uninfected dams at G18. 
lacental tissue expression of the Angpt-1 receptor Tie2, was also 
ignificantly reduced in P. berghei- infected dams compared to unin- 
ected dams (one-way ANOVA with Tukey’s multiple comparisons, 
 < 0.0 0 01; Figure 4 g). Ang-2 mRNA expression in placental tis-
ue was similar between the two groups regardless of gestational 
iming ( Figure 3 f). These experimental findings support the hu- 
an clinical data indicating disruption of systemic angiopoietins 6 y malaria during pregnancy and further indicate that angiopoi- 
tin signalling pathways at the placenta may also be disrupted. 
iven the temporal relationship between the reduction in circu- 
ating levels of Angpt-1, increased Angpt-2, and subsequent foetal 
rowth restriction in the preclinical model, we further investigated 
he role of Angpt-1 by genetic disruption. 
.3. PbA-infection of Angpt1 +/- heterozygous dams worsens foetal 
eight and viability 
Total knockout of Angpt1 is embryonic lethal [11] ; therefore, 
e used a heterozygous Angpt1 + /- mouse line, which has reduced 
ngpt-1 expression but maintains normal fecundity and birth out- 
omes in the absence of an infectious challenge ( Figure 4 d and 
igure 5 ). We tested the hypothesis that reduced maternal Angpt- 
 in the context of P. berghei infection would further exacer- 
ate adverse birth outcomes. Levels of maternal plasma Angpt-1 
Kruskall-Wallis with Dunn’s multiple comparisons, n.s.; Figure 4 a) 
nd Angpt-1 mRNA (one way ANOVA with Tukey’s multiple com- 
arisons, p = 0.046; Figure 4 d) in the placenta were decreased by 
50% in uninfected Angpt1 + /- heterozygous dams compared to 
ildtype, while levels of Angpt-2 remained similar ( Figure 4 b and 
 e). P. berghei infection resulted in decreased circulating Angpt- 
 concentrations and increased the Angpt-2/Angpt-1 ratio com- 
ared to uninfected dams, irrespective of genotype (Kruskall- 
allis with Dunn’s multiple comparisons, p < 0.01, Figure 4 a; and 
ne-way ANOVA with Tukey’s multiple comparisons, p < 0.001, 
igure 4 c). While wildtype-infected mice showed a significant in- 
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Figure 3. Experimental malaria in pregnancy recapitulates human birth phenotypes and dysregulation of angiopoietins across pregnancy. (a) Fetal weight (in grams) across 
pregnancy in dams injected with RPMI vehicle control or Plasmodium berghei (PbA) ( ∗∗∗p < 0.0 01, ∗∗∗∗p < 0.0 0 01, multiple Mann-Whitney tests with Holm-Sidak correction for 
multiple comparisons; n = 17-40 fetuses per group per gestational day (n = 5-10 pregnant mice per group per gestational day); n = 2 experimental replicates). (b) Fetal viability 
(as percentage of total fetuses) at gestational day 19 in dams injected with vehicle control or PbA ( ∗∗∗∗p < 0.0 0 01, Fisher’s exact test; n = 62-71 per group; n = 3 experimental 
replicates). (c, e, g) Maternal plasma concentrations of Angpt-1 (c) and Angpt-2 (e) across pregnancy measured by enzyme-linked immunosorbent assay (ELISA) in dams 
injected with vehicle control or PbA. Ratio of Angpt-2/Angpt-1 presented in (g). Dotted lines represent exposure group injection on gestational day 13. Bars depict mean 
and SEM ( ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0 0 01, two-way ANOVA with Bonferroni’s multiple comparisons test; n = 5-9 dams per group per gestational day; n = 2 
experimental replicates). (d, f, h) Maternal expression of Angpt-1 (d) and Angpt-2 (f) mRNA in the placenta measured by qRT-PCR in dams injected with vehicle control 
or PbA. Ratio of Angpt-2/Angpt-1 presented in (h). Dotted lines represent exposure group injection on gestational day 13. Bars depict mean and SEM ( ∗∗p < 0.01, two-way 
ANOVA with Bonferroni’s multiple comparisons test; n = 6-20 placentas per group per gestational day; n = 2 experimental replicates). 
Figure 4. Circulating protein concentrations and placental mRNA expression of angiopoietins are altered with P. berghei ANKA infection of wild type dams and further 
exacerbated in infected Angpt1 + / − heterozygous dams. (a to c) Maternal plasma levels of Angpt-1 (a) and Angpt-2 (b) measured by enzyme-linked immunosorbent assay 
(ELISA) at gestational day 19 in wildtype or Angpt1 + / − heterozygous dams injected with vehicle control or Plasmodium berghei ANKA (PbA). Ratio of Angpt-2/Angpt-1 is 
presented in (c). One Angpt-2/Angpt-1 ratio value was included in the analysis (see Methods for handling of outliers) but excluded from the visual depiction for reasons of 
scale (value = 144). Bars represent mean and SEM. ( ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0 0 01, Kruskal-Wallis test with Dunn’s multiple comparisons or one-way ANOVA with Tukey’s 
multiple comparisons test; n = 9-13 dams per group; n = 3 experimental replicates). (d to g) Maternal expression of Angpt-1 (d), Angpt-2 (e), and Tie2 (g) mRNA in the 
placenta measured by qRT-PCR at gestational day 19 in wildtype or Angpt1 + / − dams injected with vehicle control or PbA. Ratio of Angpt-2/Angpt-1 presented in (f). Boxplots 
depict median and interquartile range with min/max whiskers. ( ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, one-way ANOVA with Tukey’s multiple comparisons test or Kruskal-Wallis 














rease in maternal plasma Angpt-2, infected Angpt1 + / − dams did 
ot ( Figure 4 b). In the placenta, the ratio of Angpt-2/Angpt-1 
RNA expression trended towards highest in P. berghei -infected 
ngpt1 + / − dams (one-way ANOVA with Tukey’s multiple compar- 
sons, p = 0.052; Figure 4 f). This imbalance appeared to result from 
 significant decrease in placental expression of Angpt-1 mRNA 
n infected Angpt1 + / − dams (one-way ANOVA with Tukey’s mul- 7 iple comparisons, p < 0.01; Figure 4 d). Tie2 mRNA expression in 
he placenta was significantly reduced in response to P. berghei- 
nfection, regardless of maternal genotype (one-way ANOVA with 
ukey’s multiple comparisons, p < 0.001; Figure 4 g). 
Phenotypically, greater dysregulation of the angiopoietin axis 
n the context of P. berghei infection was associated with wors- 
ned birth outcomes. P. berghei infection in the heterozygous dams 
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Figure 5. P. berghei infection exacerbates adverse birth outcomes in Angpt1 + / −
heterozygous dams. (a) Fetal weight (in grams) at gestational day 19 from wild- 
type or Angpt1 + / − dams injected with RPMI vehicle control or Plasmodium berghei 
ANKA (PbA) ( ∗∗∗∗p < 0.0 0 01, two-way ANOVA with Tukey’s multiple comparisons 
test; n = 56-86 fetuses per group (n = 10-13 pregnant mice); from n = 3 experimental 
replicates). (b) Fetal weight (in grams) at gestational day 19 by fetal genotype (from 
Angpt1 + / − maternal background) and exposure group (not significant (ns), two-way 
ANOVA with Tukey’s multiple comparisons test; n = 20-37 fetuses per group (n = 6- 
10 pregnant mice); n = 2 experimental replicates). (c) Fetal viability (as percentage 
of total fetuses) at gestational day 19 by maternal genotype (wildtype or Angpt1 + / −) 
and exposure group ( ∗∗∗p < 0.001, Fisher’s exact test; n = 62-88 fetuses per group 
(n = 10-14 pregnant mice); from n = 3 experimental replicates). (d) Fetal viability (as 
percentage of total fetuses) at gestational day 19 by fetal genotype (from Angpt1 + / −
maternal background) and exposure group (not significant (ns), Fisher’s exact test; 





























































8  Angpt1 + / −) led to decreased foetal growth and viability (two- 
ay ANOVA with Tukey’s Multiple comparisons test, p < 0.0 0 01, 
igure 5 a; and Fisher’s exact test, p < 0.0 0 01, Figure 5 c). This effect
as driven by the maternal genotype as there was no difference 
n weight or viability between wildtype and Angpt1 + / − foetuses in 
he context of P. berghei infection ( Figure 5 b and 5 d). 
.4. Maternal Angpt-1 is involved in placental vascular development 
nd function in experimental malaria in pregnancy 
We have previously shown that compensatory placental vascu- 
ar remodelling occurs in the context of placental dysfunction (e.g., 
ncreased arterial resistance) during P. berghei infection [ 3 , 4 ]. Sev- 
ral therapeutic approaches that have improved birth outcomes in 
xperimental malaria in pregnancy, including C5a-C5aR signalling 
lockade and L-arginine supplementation, have done so by fur- 
her increasing vascular development to compensate for malaria- 
ediated placental dysfunction [ 3 , 4 ]. We hypothesized that the ob- 
erved deficiency in circulating Angpt-1 was worsening birth out- 
omes by inhibiting compensatory placental vascular remodelling 
n the opposite manner to C5a-C5aR blockade or L-arginine. To 
est this hypothesis, we used micro-CT to image placental vascu- 
ature in wildtype and Angpt1 + / − infected and uninfected pregnant 
ice ( Figure 6 c, Figure S4). As reported [ 3 , 4 ], wildtype P. berghei -
nfected dams had an increased total number of placental vessel 
egments, driven by an increase in small vessel segments (35-75 
m) compared to uninfected mice (two-way ANOVA with Dunn’s 
ultiple comparison post-hoc test, p < 0.001, Figure 6 a; and Fig- 
res S5a and S5b). The compensatory increase in placental vascula- 
ure characteristic of P. berghei infection was abrogated in Angpt1 + /- 
ams ( Figure 6 a and Figure S5A and S5B). Regardless of infection, 
ngpt1 + / − placentas had fewer large vessel segments ( > 200 μm) 
Figure S5d), a phenotype consistent with previous research show- 
ng that Angpt-1 promotes large vessel size [ 15 , 34 ]. A functional
eadout of placental vasculature showed that infection elevated 
lacental arterial resistance (two-way ANOVA with Tukey’s mul- 
iple comparisons, p < 0.01; Figure 6 b). Genetic Angpt-1 deficiency 
xacerbated the effect of infection, with the highest arterial resis- 
ance observed in infected Angpt1 + / − mice; however, the increase 
id not reach significance ( Figure 6 b). Collectively, our preclinical 
ata support a hypothesis whereby experimental malaria in preg- 
ancy induces a reduction in maternal Angpt-1 resulting in dis- 
upted placental vascular remodelling required for optimal foetal 
rowth and survival. 
. Discussion 
Dysregulation of the angiopoietin-Tie2 axis contributes to the 
athogenesis of severe infections and host response to infection, 
ncluding sepsis, severe bacterial infections, and non-pregnancy se- 
ere malaria [35] . Several cross-sectional studies have shown dys- 
egulation of Angpt-1 and Angpt-2 at delivery in women with an- 
enatal malaria [ 3 , 5 , 24 , 25 ]. Here, we provide the first mechanis-
ic evidence that implicates this axis in the pathogenesis of ad- 
erse birth outcomes associated with malaria during pregnancy. 
e show that Angpt-1 and the Angpt-2/Angpt-1 ratio are per- 
urbed across pregnancy in women with evidence of placental 
alaria, as well as in pregnancies resulting in adverse live birth 
utcomes. We confirm these observations in a preclinical model of 
alaria in pregnancy and provide direct experimental evidence for 
 synergistic impact of P. berghei infection and reduced circulat- 
ng Angpt-1 levels on foetal weight and viability. Finally, we show 
hat Angpt-1 may play a protective role in placental adaptations to 
alaria in pregnancy, and that when it is depleted, compensatory 
ascular remodelling mechanisms are impaired and adverse birth 
utcomes increase. 
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Figure 6. Angpt-1 is required for P. berghei mediated compensatory placental vascular remodeling. (a) Cumulative distribution of placental vessels by vessel diameter from 
wildtype (gray lines) or Angpt1 + / − (red lines) Plasmodium berghei ANKA (PbA) infected or uninfected dams. Lines represent mean and SEM of vessels greater than the 
threshold diameter ( > 35μm) ( ∗∗∗p < 0.001; two-way ANOVA of spline parameters with Dunn’s multiple comparisons post-hoc test; n = 7-8 placentas per group (n = 3-5 pregnant 
mice); n = 2 experimental replicates). (b) Arterial resistance in placentas from uninfected and PbA-infected, wildtype or Angpt1 + / −, dams. Boxplots represent median and 
interquartile range with min/max whiskers. ( ∗∗p < 0.01, ∗∗∗p < 0.001; two-way ANOVA with Tukey’s multiple comparisons test; n = 6-7 placentas per group (n = 3-4 pregnant 
mice); n = 2 experimental replicates). (c) Representative micro-CT imaging of placentas at gestational day 18 from wildtype and Angpt1 + / − PbA-infected dams, color-coded by 



































Angpt-1, Angpt-2, and Tie2 are expressed in the placenta early 
n development and are necessary for embryonic, or in the case 
f Angpt-2, early postnatal survival [ 11 , 14 , 36 , 37 ]. On endothelial
ells, Angpt-1 and Angpt-2 act primarily as agonist and antagonist, 
espectively, to their receptor Tie2 [38] . Increasing concentrations 
f Angpt-2 block the activity of Angpt-1, highlighting the impor- 
ance of the Angpt-2/Angpt-1 ratio in the angiopoietin-Tie2 sig- 
alling axis [38] . Biologically, Angpt-1 stabilizes newly formed ves- 
els by promoting interactions between endothelial cells and the 
urrounding extracellular matrix and supporting cells [11] . Angpt- 
 can block this activity, leading to either increased vascular re- 
odelling and growth or vascular regression depending on the 
resence or absence of other factors including vascular endothe- 
ial growth factor (VEGF) [ 38 , 39 ]. In a healthy pregnancy, placental
xpression of Angpt-1 increases as vasculature becomes more es- 
ablished across pregnancy, while Angpt-2 and Tie2 decrease [12] . 
erturbations to the longitudinal dynamics of the angiopoietin sig- 
alling axis are associated with adverse pregnancy outcomes, in- 9 luding preeclampsia and foetal growth restriction [ 12 , 17 , 40 , 41 ].
ur clinical data showed decreased Angpt-1 and an increased 
ngpt-2/Angpt-1 ratio across pregnancy in women with evidence 
f placental malaria. In primigravid pregnancies, Angpt-2 was also 
ignificantly elevated across gestation in women with evidence of 
lacental malaria. In pregnancies resulting in adverse live birth 
utcomes, the Angpt-2/Angpt-1 ratio was significantly lower in the 
ate third trimester compared to pregnancies with normal birth 
utcomes. This pattern has been seen in other pathologic preg- 
ancies, including pregnancies complicated by preeclampsia [18] . 
iven that there is a higher rate of adverse birth outcomes in 
regnancies complicated with malaria compared to those that are 
ot, we hypothesize that reducing Angpt-2 and increasing Angpt-1 
ay be a late compensation mechanism in pathologic pregnancies, 
o stabilize placental vasculature and mitigate adverse birth out- 
omes. However, in the context of malaria in pregnancy our clini- 
al and preclinical data indicate that a high Angpt-2/Angpt-1 ratio 






























































































































s maintained, preventing compensation, and resulting in increased 
dverse birth outcomes compared to non-malarial pregnancies. 
Our preclinical experiments mimic our human cohort data 
n terms of decreased circulating Angpt-1, increased Angpt-2 (in 
rimigravid pregnancies), and an increased peripheral plasma 
ngpt-2/Angpt-1 ratio in response to malaria in pregnancy. While 
he dysregulation of circulating Angpt-1 and the Angpt-2/Angpt- 
 ratio were mirrored by their placental tissue mRNA expres- 
ion, the dynamics of Angpt-2 alone were not. Circulating Angpt- 
 was increased in response to P. berghei infection, but placental 
RNA expression remained unchanged. This discrepancy is sup- 
orted by data from non-malarial pathologic pregnancies, includ- 
ng foetal growth restriction and preeclampsia, which describe dif- 
erences between circulating maternal angiopoietins and placental 
RNA levels [18] . In the context of experimental malaria in preg- 
ancy, the mismatch between circulating levels versus placental 
ngpt-2 transcript levels may not be due to placental mRNA per se 
ut could be due to systemic endothelial cell activation caused by 
alaria and associated inflammation in the maternal circulation, 
s well as release of preformed Angpt-2 from Weibel-Palade bod- 
es in the endothelium of the placental vasculature [35] . Placental 
xpression of Tie2 was also significantly reduced in our P. berghei - 
nfected dams. Decreased expression of Tie2 would be expected to 
educe Tie2 signalling and compromise placental endothelial func- 
ion, even in the presence of Angpt-1 [42] . A critical role for Angpt-
 over Angpt-2 in this mechanism is supported by data from pre- 
linical models of severe malaria, which show that despite high 
evels of circulating Angpt-2, its inhibition did not improve out- 
omes [19] . Conversely, genetic and pharmacological strategies es- 
ablished Angpt-1 as necessary for survival and maintaining en- 
othelial integrity at the blood-brain barrier [19] . 
Aberrant placental vascular development and remodelling, re- 
ulting in placental dysfunction and insufficiency, has emerged as 
 key mediator of adverse birth outcomes in the context of ma- 
ernal infections including malaria [ 3 , 4 , 6 , 9 ]. Inflammatory and an-
iogenic pathways, and the interactions between them, have es- 
ential physiologic roles in healthy placental and foetal develop- 
ent, and their combined dysregulation in pathologic pregnan- 
ies and malaria in pregnancy is well-documented [ 2 , 3 , 43-47 ]. Ev-
dence from malaria in pregnancy, as well as other infections and 
athologies, suggests a relationship between complement dysregu- 
ation (e.g., excessive C5a) and the angiopoietin family [ 3 , 43 , 48 ]. In
regnant women with P. falciparum infection, structural equation 
odelling provided a statistical hierarchical relationship between 
5a and the angiopoietins, suggesting C5a was an upstream ini- 
iator, reducing Angpt-1 levels to ultimately mediate foetal growth 
estriction [3] . Future studies should directly investigate the puta- 
ive hierarchical relationship between C5a and Angpt-1 in malaria 
n pregnancy to further elucidate targetable molecular pathways in 
he pathogenesis of adverse birth outcomes. 
Collectively, our clinical and preclinical data, along with pre- 
xisting data, support the idea that the angiopoietin-Tie2 axis 
ould be a modifiable pathway to improve birth outcomes in 
alaria in pregnancy [49] . There is precedent from other severe 
alaria outcomes that are mediated through the angiopoietin-Tie2 
athway, where therapeutic administration of recombinant Angpt- 
 improved survival and the integrity of the blood brain barrier 
n a preclinical model of cerebral malaria [19] . However, the high 
ost of pharmaceutical recombinant proteins and monoclonal anti- 
odies [50] impedes their use in low-resource settings, where the 
urden of malaria is highest. Furthermore, without also rectifying 
alaria-induced reductions in Tie2 expression in the placenta, ad- 
inistering recombinant Angpt-1 may not be effective [42] . As an 
lternative, we have shown that dietary supplementation with L- 
rginine, a precursor to nitric oxide, increases placental expression 
f both Angpt-1 and Tie2 in malaria in pregnancy [4] . In the con-10 ext of experimental malaria in pregnancy, L-arginine supplemen- 
ation improved foetal weight and viability and did so by a com- 
ensatory increase in placental vasculature [4] . L-arginine is an in- 
xpensive intervention with a known safety profile in pregnancy, 
nd evidence for its capacity to modulate several pathways rele- 
ant to the pathogenesis of adverse birth outcomes in malaria in 
regnancy, including the angiopoietin-Tie2 pathway [ 4 , 49 , 51 ]. 
.1. Caveats and Limitations 
This study presents a novel longitudinal assessment of an- 
iopoietin dynamics across pregnancies complicated by Plasmod- 
um falciparum infection. Our findings are strengthened by the 
ombination of human data and preclinical mechanistic data to 
upport a clinically relevant hypothesis. Dysregulation of the an- 
iopoietins across gestation was common to both placental malaria 
nd adverse birth outcomes in the human cohort, yet these data 
re associative and do not establish causality. Using a preclinical 
ouse model of malaria in pregnancy enables more mechanistic 
nvestigations that would be challenging to conduct for ethical and 
ogistical reasons in human populations. Although there are dif- 
erences between the mouse and the human placenta, there are 
lso structural and molecular similarities, especially in the con- 
ext of vascular development and function, including high con- 
ordance in proteomic and transcriptomic profiles [52–54] . Impor- 
antly, Angpt-1 and Angpt-2 sequences are almost identical be- 
ween mice and humans [ 30 , 55 ], and there is strong precedent
or their analogous roles in humans and mice in both physiological 
rocesses and disease pathogenesis [ 19 , 27 , 56 ]. However, there are
imitations in the translation from human pregnancy to an exper- 
mental model of malaria in pregnancy. The experimental model 
ses malaria-naïve, nulliparous mice. This most closely simulates 
nfections in nonimmune primigravidae (for whom the human data 
ost closely matched the preclinical data), and results in higher 
arasitaemia and more severe acute disease than would be ex- 
ected in human pregnancies. This could in part explain discrepan- 
ies in angiopoietin-Tie2 profiles between mouse and human data 
i.e., greater effect of malaria on Angpt-2 in the mouse model). Fur- 
hermore, our data revealed a complex relationship between sys- 
emic angiopoietins and placental Angpt-Tie2 signalling, and their 
elative importance during malaria in pregnancy. In the preclinical 
enetic model of malaria, systemic levels of Angpt-1 and -2 did not 
xplain the synergistic effect of Angpt1 + / − genotype and PbA infec- 
ion on adverse birth outcomes (worst outcomes in PbA-infected 
ngpt1 + / − mice). Differences in placental Angpt-1 mRNA expres- 
ion and placental vasculature in infected Angpt1 + / − dams bet- 
er mirrored the exacerbated birth outcomes; however, the precise 
echanistic pathway requires further investigation to fully eluci- 
ate. While our clinical data would be strengthened by a matching 
ssessment of human placental Tie2 and Angpt-2/Angpt-1 expres- 
ion, collecting placental samples in a large cohort of women in 
 low-income setting would be difficult. The preclinical model al- 
owed us to more feasibly establish a link between malaria during 
regnancy, systemic, and placental dysregulation of the angiopoi- 
tins, and provided further advantages including the ability to con- 
uct micro-CT analysis of the full placental vascular tree, which 
ould not have been possible in the clinical study. 
Despite the limitations with directly comparing human and ani- 
al studies, the data presented here provide preliminary evidence 
or a mechanistic link between malaria-associated changes in the 
ngiopoietin-Tie2 axis, alterations in placental vascular develop- 
ent and remodelling, and adverse birth outcomes. Previous cross- 
ectional studies in P. falciparum -infected pregnancies showed dis- 
uptions to the angiopoietins at delivery, at which point interven- 
ion is futile. Here, we combined clinical and preclinical data to 
rovide a more comprehensive picture of the disruption of Angpt-1 






























































[  nd Angpt-2 homeostasis across gestation and its subsequent im- 
act on placental vascular development and birth outcomes. 
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